Possible Genotype-Phenotype Correlations in Children with Mild Clinical Course of Canavan Disease

Abstract

Canavan disease is characterised as a rare, neurodegenerative disease that usually causes death in early childhood. It is an autosomal recessive disorder due to an aspartoacylase (ASPA) deficiency. The causative gene has been mapped to chromosome 17 pter-p13. Here we describe three affected children from two Greek families with an unusually mild course of Canavan disease. All children presented with muscular hypotonia and macrocephaly. Diagnosis was based on elevated N-acetylaspartate in urine, reduced aspartoacylase activity in fibroblasts, and marked white matter changes on cerebral imaging. All three affected individuals exhibited continuous psychomotor development without any regression. Genetic analyses revealed compound heterozygous mutations (Y288 C; F295 S) in two individuals. The Y288 C variant was previously described in a child with macrocephaly, mild developmental delay, increased signal intensity in the basal ganglia, partial cortical blindness and retinitis pigmentosa, and slightly elevated N-acetylaspartate in the urine. Demonstration of the same variant in two unusually mildly affected Canavan disease patients and absence of this variant in 154 control chromosomes suggest a possible pathogenic role in mild Canavan disease. In the third individual, two homozygous sequence variants were identified, which comprise the known G274R mutation and a novel K213E variant.

Key words

Mild Canavan disease - aspartoacylase - ASPA - leukodystrophy

References

• 1 Baslow M H. Canavan's spongioform leukodystrophy.  J Mol Neurosci. 2000;  15 61-69
• 2 Baslow M H. Evidence supporting role for N-acetyl-aspartate as a molecular water pump in myelinated neurons in the central nervous system.  Neurochem Int. 2002;  4 295-300
• 3 Gordon N. Canavan disease: a review of recent developments.  Eur J Pediatr Neurol. 2000;  5 65-69
• 4 Jakobs C, ten Brink H J, Langelaar S A, Zee T, Stellaard F, Macek M. et al . Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease.  J Inherit Metab Dis. 1991;  14 653-660
• 5 Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A. et al . Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.  Hum Gene Ther. 2002;  13 1391-1412
• 6 Kaul R, Balamurugan K, Gao G P, Matalon R. Canavan disease: genomic organisation and localization of human ASPA to 17 p13-ter and conservation of the ASPA gene during evolution.  Genomics. 1994;  15 364-370
• 7 Kaul R, Gao G P, Aloya M, Balamurugan K, Petrosky A, Michals K, Matalon R. Canavan disease: mutations among Jewish and non-Jewish patients.  Am J Hum Genet. 1994;  55 34-41
• 8 Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.  Am J Med Genet. 1988;  29 463-471
• 9 Sener R N. Canavan disease: diffusion magnetic resonance imaging findings.  J Comput Assist Tomogr. 2003;  27 30-33
• 10 Shaag A, Anikster Y, Christensen E, Glustein J Z, Fois A, Michelakakis H. et al . The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients.  Am J Hum Genet. 1995;  57 572-580
• 11 Surendran S, Bamforth F J, Chan A, Tyring S K, Goodman S I, Matalon R. Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem.  J Child Neurol. 2003;  18 809-812
• 12 Traeger E C, Rapin I. The clinical course of Canavan disease.  Pediatr Neurol. 1998;  18 207-212
• 13 Zafeiriou D I, Kleijer W J, Maroupoulos G, Anastasiou A L, Augoustidou-Savvopoulou P, Papadopoulou F. et al . Protracted course of N-acetylaspartic aciduria in two non-Jewish siblings: identical clinical and magnetic resonance imaging findings.  Brain Dev. 1999;  21 205-208
• 14 Zeng B J, Wang Z H, Ribeiro L A, Leone P, De Gasperi R, Kim S J. et al . Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease.  J Inherit Metab Dis. 2002;  25 557-570